Truist Securities Reiterates Buy on Elevance Health, Lowers Price Target to $520

Benzinga · 10/18 13:35
Truist Securities analyst David Macdonald reiterates Elevance Health (NYSE:ELV) with a Buy and lowers the price target from $620 to $520.